22.16 +0.12 (0.57%)
Pre-market: 9:05AM EST
|Bid||22.17 x 3000|
|Ask||22.19 x 100|
|Day's range||21.32 - 22.08|
|52-week range||8.31 - 24.43|
|PE ratio (TTM)||5.62|
|Forward dividend & yield||0.00 (0.00%)|
|1y target est||N/A|
Generic-drug makers were hit Thursday after hospitals said they would make medicines themselves to circumvent high prices.
A federal judge signaled he would approve a $290 million settlement reached by Pershing Square, Valeant and the shareholders of Allergan who had alleged the two firms improperly profited from their failed ...
Shares of Valeant Pharmaceuticals International (VRX) have more than doubled the S&P 500's return during the past 12 months. H.C. Wainwright's Raghuram Selvaraju is warming to the stock. Valeant has made "significant strides" in moving its pipeline forward in recent months, he writes, while also making "substantial progress" on its debt.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) laid out a detailed restructuring plan for the company to turn around its ailing business due to a number of challenges it’s facing.
Shares of Valeant Pharmaceuticals International (VRX) are higher on Friday, following acceptance of the application of one of its subsidiaries' acne medications. Valeant said that the Food and Drug Administration approved its New Drug Application for its tretinoin acne lotion, with an approval date of August 27, 2018.
Pershing Square Holdings, the hedge fund operated by noted activist investor Bill Ackman, on Wednesday announced it was slashing its management fees, a move related to the settlement of two class-action ...
Valeant Pharmaceuticals International Inc. became a household name with its historic rise and fall. Reviving the drugmaker is proving a unique challenge.
In 3Q17, Valeant's (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.
In 3Q17, Valeant’s Xifaxan reported revenues of $286 million, which was ~5% higher on a YoY (year-over-year) basis and a 23% rise quarter-over-quarter.
In 3Q17, Valeant Pharmaceuticals’ (VRX) branded prescription drugs generated revenues of ~$633 million, compared with $766 million in 3Q16.
In 3Q17, Valeant Pharmaceuticals’ Bausch + Lomb’s Soflens generated revenues of $83 million, which was ~5% higher on a YoY basis and ~9% higher QoQ.
In 3Q17, Valeant Pharmaceuticals’ Bausch + Lomb, generated revenues of $1.25 billion, which reflected a ~1% growth on a YoY basis.
In 3Q17, Valeant Pharmaceuticals generated revenues of $2.2 billion, which was ~10% lower YoY (year-over-year) and 1% lower QoQ (quarter-over-quarter).
Executives of Pershing Square Capital Management and Valeant Pharmaceuticals International Inc. were ordered to come to court to defend the fairness of the $290 million settlement of an insider-trading ...
Valeant Pharmaceuticals International Inc. shares rose nearly 3% in premarket trade on Wednesday after the company said it used cash on hand to pay down an additional $300 million in senior secured term ...
Valeant (VRX) and Pershing Square decided to resolve the claims of the long standing Allergan lawsuit for $290 million. Valeant will now pay 33% of the costs, down from the previous agreement of 60%.
The hearing, set for Jan. 16, comes after Pershing Square and Valeant last week decided to pay $290 million (£213.42 million) to settle the lawsuit that accused them of insider trading before bidding for Allergan Plc (AGN.N) in 2014. The lawsuit was filed on behalf of investors who sold Allergan shares in the two months before Pershing Square Capital Management and Valeant made an unsolicited $51 billion bid for Allergan.
The hearing, set for Jan. 16, comes after Pershing Square and Valeant last week decided to pay $290 million to settle the lawsuit that accused them of insider trading before bidding for Allergan Plc (AGN.N) in 2014. The lawsuit was filed on behalf of investors who sold Allergan shares in the two months before Pershing Square Capital Management and Valeant made an unsolicited $51 billion bid for Allergan.